The IL-4/IL-13 blocker dupilumab is the first approved biologic for therapy with atopic dermatitis (AD). It is remarkably effective, but a relatively frequent side effect is conjunctivitis, which is best managed preventively .
Dupilumab is a highly effective therapy for patients with moderate-to-severe AD. When applied together with topical corticosteroids, 39% of patients gained a complete or almost complete healing of skin lesions (corresponding to IGS 0/1) with this drug, which could be maintained over a year . “This is a huge step forward for the management of patients with moderate-to-severe disease,” said Prof. Tilo Biedermann (Helmholtz Center Munich, Germany). In real life, he has seen a very similar effect: patients respond quickly and about half of patients gain an EASI 90 response after 8 weeks.
“A small drawback of this effect is the conjunctivitis, which we see in 8 to 10% of our patients,” said Prof. Biedermann. Pathogenesis, cli...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Biologics: increasingly used in paediatric dermatology Next Article
JAK inhibition plus TCS lead to high clearance rates in AD »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.